HPV REFERENCES

REFERENCES

  1. Lew JB, Simms K, et al. Effectiveness Modelling and Economic Evaluation of Primary HPV Screening for Cervical Cancer Prevention in New Zealand. PLoS One, 2016;11(5).
  2. Beutner KR, Tyring S. Human papillomavirus and human disease. Am J Med, 1997 May 5;102(5A):9-15.
  3. Castle PE, Maza M. Prophylactic HPV Vaccination: past, present, and future. Epidemiology and Infection, 2015;144(3):449-68.
  4. Clifford GM, Gallus S, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet, 2005 Sep 17-23;366(9490):991-8.
  5. de Sanjose S, Diaz M, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis, 2007 Jul;7(7):453-9.
  6. Collins SI, Mazloomzadeh S, et al. Proximity of first intercourse to menarche and the risk of human papillomavirus infection: a longitudinal study. International Journal of Cancer, 2005 Apr 10;114(3):498-500.
  7. Winer RL, Lee S-K, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. [see comment] [Erratum in: Am J Epidemiol, 2003 May 1;157(9):858]. Am J Epidemiol, 2003 Feb 1;157(3):218-26.
  8. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol, 2005 Mar;32(Suppl 1):S16-24.
  9. Rodriguez A, Schiffman M, et al. Longitudinal, prospective study of type-specific carcinogenic HPV infections over 7 years in Guanacaste, Costa Rica. Proceedings of the 24th International Papillomavirus Conference and Clinical Workshop, Beijing, China, 2007. Abstract 7B-02.
  10. Sycuro LK, Xi LF, et al. Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students. J Infect Dis, 2008 Oct 1;198(7):971-8.
  11. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine, 2006 Mar 30;24 Suppl 1:S1-15.
  12. Rositch AF, et al. Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women. Cancer Research, 2012;72(23):6183-90.
  13. Brown DR, Weaver B. Human papillomavirus in older women: new infection or reactivation? J Infect Dis, 2013;207(2):211-2.
  14. Strickler HD, Burk RD, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus positive women. J Natl Cancer Inst, 2005;97:577.
  15. Shvetsov YB, et al. Duration and clearance of anal human papillomavirus (HPV) infection among women: the Hawaii HPV cohort study. Clinical Infectious Diseases, 2009;48(5):536-46.
  16. Castro FA, et al. Prevalence of and risk factors for anal human papillomavirus infection among young healthy women in Costa Rica. J Infect Dis, 2012;206(7):1103-10.
  17. Beachler DC, et al. Natural history of anal vs oral HPV infection in HIV-infected men and women. J Infect Dis, 2013;208(2):330-9.
  18. Santoso JT, et al. Anal intraepithelial neoplasia in women with genital intraepithelial neoplasia. Obstetrics & Gynecology, 2010;116(3):578-82.
  19. Dunne EF, Nielson CM, et al. Prevalence of HPV infection among men: A systematic review of the literature. J Infect Dis, 2006 Oct 15;194(8):1044-57.
  20. Nyitray AG, et al. The prevalence of genital HPV and factors associated with oncogenic HPV among men having sex with men and men having sex with women and men: the HIM study. Sexually Transmitted Diseases, 2011;38(10):932.
  21. Giuliano AR, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. The Lancet, 2011;377(9769):932-40.
  22. Nyitray AG, et al. Age-specific prevalence of and risk factors for anal human papillomavirus (HPV) among men who have sex with women and men who have sex with men: the HPV in men (HIM) study. J Infect Dis, 2011;203(1):49-57.
  23. Anal cancer and its screening using digital ano-rectal examination (DARE) in men living with HIV who have sex with men. (Accessed at www.ashm.org.au/hiv/management-hiv/anal-cancer.)
  24. Chin-Hong PV, Vittinghoff E, et al. Age-specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study. J Infect Dis, 2004 Dec 15;190(12):2070-6.
  25. Goldstone S, Palefsky JM, et al. Prevalence of and risk factors for human papillomavirus (HPV) infection among HIV-seronegative men who have sex with men. J Infect Dis, 2011 Jan 1;203(1):66-74.
  26. Chin-Hong PV, Husnik M, et al. Anal human papillomavirus infection is associated with HIV acquisition in men who have sex with men. Aids, 2009 Jun 1;23(9):1135-42.
  27. Winer RL. Genital Human Papillomavirus Infection: Incidence and risk factors in a cohort of female university students. Am J Epidemiol, 2003;157(3):218-26.
  28. Shew ML, Weaver B, et al. High Frequency of Human Papillomavirus Detection in the Vagina Before First Vaginal Intercourse Among Females Enrolled in a Longitudinal Cohort Study. J Infect Dis, 2012;207(6):1012-5.
  29. Karlsson R, Jonsson M, et al. Lifetime Number of Partners as the Only Independent Risk Factor for Human Papillomavirus Infection. Sexually Transmitted Diseases, 1995;22(2):119-27.
  30. Nyitray AG, Menezes L, et al. Genital Human Papillomavirus (HPV) Concordance in Heterosexual Couples. J Infect Dis, 2012;206(2):202-11.
  31. D'Souza G, Agrawal Y, et al. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis, 2009 May 1;199(9):1263-9.
  32. Coutlee F, Trottier AM, et al. Risk factors for oral human papillomavirus in adults infected and not infected with human immunodeficiency virus. Sex Transm Dis, 1997 Jan;24(1):23-31.
  33. Kreimer AR, Alberg AJ, et al. Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. J Infect Dis, 2004 Feb 15;189(4):686-98.
  34. Panici PB, Scambia G, et al. Oral condyloma lesions in patients with extensive genital human papillomavirus infection. American Journal of Obstetrics & Gynecology, 1992 Aug;167(2):451-8.
  35. Yeudall WA, Campo MS. Human papillomavirus DNA in biopsies of oral tissues. Journal of General Virology, 1991 Jan;72(Pt 1):173-6.
  36. Wilson L, Pawlita M, et al. Seroprevalence of 8 Oncogenic Human Papillomavirus Genotypes and Acquired Immunity Against Reinfection. J Infect Dis, 2014;201(3):448-55.
  37. Wentzensen N, Rodriguez AC, et al. A Competitive Serological Assay Shows Naturally Acquired Immunity to Human Papillomavirus Infections in the Guanacaste Natural History Study. J Infect Dis, 2011;204(1):94-102.
  38. Tang CK, Shermeta DW, et al. Congenital condylomata acuminata. American Journal of Obstetrics & Gynecology, 1978 Aug 15;131(8):912-3.
  39. Obalek S, Jablonska S, et al. Condylomata acuminata in children: frequent association with human papillomaviruses responsible for cutaneous warts. J Am Acad Dermatol, 1990 Aug;23(2 Pt 1):205-13.
  40. Bergeron C, Ferenczy A, et al. Underwear: contamination by human papillomaviruses. [See comment]. American Journal of Obstetrics & Gynecology, 1990 Jan;162(1):25-9.
  41. Ferenczy A, Bergeron C, et al. Human papillomavirus DNA in fomites on objects used for the management of patients with genital human papillomavirus infections. Obstetrics & Gynecology, 1989 Dec;74(6):950-4.
  42. Wen LM, Estcourt CS, et al. Risk factors for the acquisition of genital warts: are condoms protective? Sexually Transmitted Infections, 1999;75(5):312-6.
  43. Manhart LE, Koutsky LA. Do Condoms Prevent Genital HPV Infection, External Genital Warts, or Cervical Neoplasia? Sexually Transmitted Diseases, 2002;29(11):725-35.
  44. Winer RL, Hughes JP, et al. Condom Use and the Risk of Genital Human Papillomavirus Infection in Young Women. N Engl J Med, 2006;354(25):3645-54.
  45. Hogewoning CJ, Bleeker MC, et al. Condom Use Promotes Regression of Cervical Intraepithelial Neoplasia and Clearance of Human Papillomavirus: A randomized clinical trial. International Journal of Cancer, 2003;107(5):811-6.
  46. Bleeker MC, Hogewoning CJ, et al. Condom use promotes regression of human papillomavirus-associated penile lesions in male sexual partners of women with cervical intraepithelial neoplasia. International Journal of Cancer, 2003;107(5):804-10.
  47. Bleeker MCG, Berkhof J, et al. HPV type concordance in sexual couples determines the effect of condoms on regression of flat penile lesions. British Journal of Cancer, 2005;92(8):1388-92.
  48. Lynch P. Skin coloured lesions. In: Edwards L, Lynch P, eds. Genital Dermatology Atlas. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2011.
  49. Burkhart C. The endogenous, exogenous, and latent infections with human papillomavirus. International Journal of Dermatology, 2004 Jul;43(7):548-9.
  50. Bunker C, Neill S. Male genital dermatology In: Burns T, Breathnach S, et al, eds. Rook's textbook of Dermatology. In: Blackwell Publishing; 2004.
  51. Sterling J. Anogential Warts. In: Burns T, Breathnach S, et al, eds. Rook's textbook of Dermatology. In: Blackwell Publishing 2004:45-7.
  52. Bornstein J, Bogliatto F, et al. The 2015 International Society for the Study of Vulvovaginal Disease (ISSVD) Terminology of Vulvar Squamous Intraepithelial Lesions. Journal of Lower Genital Tract Disease, 2016;20(1):11-4.
  53. Bunker C, Neill S. Female genital dermatology In: Burns T, Breathnach S, et al, eds. Rook's textbook of Dermatology. In: Blackwell Publishing; 2004:70.
  54. Sterling J. Vuval intraepithelial neoplasia, penile intraepithelial neoplasia and Bowenoid papulosis. In: Burns T, Breathnach S, et al, eds. Rook's textbook of Dermatology. In: Blackwell Publishing 2004:55-6.
  55. Bunker C, Neill S. Eythroplasia of Queyrat, Bowen's disease of the penis and bowenoid papulosis In: Burns T, Breathnach S, et al, eds. Rook's textbook of Dermatology. In: Blackwell Publishing; 2004:59.
  56. Workowski KA, Berman S. CDC Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep, 2010 Dec 17;59(RR-12):1-110.
  57. Ho GY, Bierman R, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med, 1998 Feb 12;338(7):423-8.
  58. Grillo-Ardila CF, Angel-Müller E, et al. Imiquimod for anogenital warts in non-immunocompromised adults. Cochrane Database of Systematic Reviews, 2014 (11).
  59. Lacey CJN, Woodhall SC, et al. IUSTI: 2010 European Guideline for the Management of Anogenital Warts in Adults. (Accessed July 2011, at http://www.iusti.org/regions/europe/euroguidelines.htm.)
  60. Beutner KR, Wiley DJ. Recurrent external genital warts: a literature review. Papillomavirus Report, 1997;8:69-74.
  61. UK National Guideline on the Management of Anogenital Warts. 2015. (Accessed at https://www.bashh.org/documents/UK%20national%20guideline%20on%20Warts%202015%20FINAL.pdf.)
  62. Gunter J. Genital and perianal warts: new treatment opportunities for human papillomavirus infection. American Journal of Obstetrics & Gynecology, 2003 Sep;189(3 Suppl):S3-11.
  63. 2015 Sexually Transmitted Diseases Treatment Guidelines: Anogenital Warts. (Accessed at www.cdc.gov/std/tg2015/warts.htm.)
  64. Muñoz-Santos C, Pigem R, et al. Nuevos tratamientos en la infección por virus del papiloma humano. Actas Dermo-Sifiliográficas, 2013;104(10):883-9.
  65. Forman D, et al. Global burden of human papillomavirus and related diseases. Vaccine, 2012;30:F12-23.
  66. All Cancers (excluding non-melanoma skin cancer): Estimated Incidence, Mortality and Prevalence Worldwide in 2012. (Accessed at globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.)
  67. Beral V. Cancer of the cervix: a sexually transmitted infection? Lancet, 1974 May 25;1(7865):1037-40.
  68. IARC. Monographs on the evaluation of carcinogenic risks to humans. Human Papillomaviruses, 1995;64.
  69. Walboomers JM, Jacobs MV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. [See comment]. J Pathol, 1999 Sep;189(1):12-9.
  70. Bosch FX, Lorincz A, et al. The causal relation between human papillomavirus and cervical cancer. [See comment]. J Clin Pathol, 2002 Apr;55(4):244-65.
  71. Simonella LM, Lewis H, et al. Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand. BMC Infectious Diseases, 2013;12(114).
  72. Sykes P, Gopala K, et al. Type distribution of human papillomavirus among adult women diagnosed with invasive cervical cancer (stage 1b or higher) in New Zealand. BMC Infectious Diseases, 2014;14:374.
  73. Kang Y-J, Lewis H, et al. Pre-vaccination type-specific HPV prevalence in confirmed cervical high grade lesions in the Māori and non-Māori populations in New Zealand. BMC Infectious Diseases, 2015;15(365).
  74. NCSP Annual Report 2014. (Accessed at www.nsu.govt.nz/system/files/page/ncsp-annual-report-2014-jul17.pdf.)
  75. Schiffman M, et al. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis, 2007;195(11):1582-9.
  76. Rodríguez AC, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. Journal of the National Cancer Institute, 2008;100(7):513-7.
  77. Moscicki A-B, Schiffman M, et al. Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine, 2006;24(Suppl 3):S42-51.
  78. McCredie MR, Sharples KJ, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. [See comment]. Lancet Oncology, 2008 May;9(5):425-34.
  79. Winer RL, Kiviat NB, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis, 2005 Mar 1;191(5):731-8.
  80. Schiffman M, Herrero R, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology, 2005 Jun 20;337(1):76-84.
  81. Carcinoma of the cervix and tobacco smoking: Collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. International Journal of Cancer, 2006 Mar 15;118(6):1481-95.
  82. McIntyre-Seltman K, Castle PE, et al. Smoking is a risk factor for cervical intraepithelial neoplasia grade 3 among oncogenic human papillomavirus DNA-positive women with equivocal or mildly abnormal cytology. Cancer Epidemiol Biomarkers Prev, 2005 May;14(5):1165-70.
  83. Munoz N, Castellsague X, et al. Chapter 1: HPV in the etiology of human cancer. Vaccine, 2006;24(Suppl 3):S1-10.
  84. Cogliano V, Grosse Y, et al. Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. [See comment]. Lancet Oncology, 2005 Aug;6(8):552-3.
  85. Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. International Journal of Cancer, 2006 Sep 1;119(5):1108-24.
  86. Silverberg MJ, et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clinical Infectious Diseases, 2012;54(7):1026-34.
  87. de Sanjosé S, Alemany L, et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer, 2013 Nov;49(16):3450-61.
  88. Jones RW, Rowan DM, et al. Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstetrics & Gynecology, 2005 Dec;106(6):1319-26.
  89. Derkay CS, Wiatrak B. Recurrent respiratory papillomatosis: a review. The Laryngoscope, 2008;118(7):1236-47.
  90. Beutner KR, Reitano MV, et al. External genital warts: report of the American Medical Association Consensus Conference. AMA Expert Panel on External Genital Warts. Clinical Infectious Diseases, 1998 Oct;27(4):796-806.
  91. Silverberg MJ, Thorsen P, et al. Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstetrics & Gynecology, 2003 Apr;101(4):645-52.
  92. Tasca RA, Clarke RW. Recurrent respiratory papillomatosis. Arch Dis Child, 2006 Aug;91(8):689-91.
  93. Mandelbrot L. Vertical transmission of viral infections. Curr Opin Obstet Gynecol, 1998 Apr;10(2):123-8.
  94. Jayasinghe Y, Garland SM. Genital warts in children: what do they mean? Arch Dis Child, 2006 Aug;91(8):696-700.
  95. Brisson J, Roy M, et al. Condyloma and intraepithelial neoplasia of the uterine cervix: a case-control study. [See comment]. Am J Epidemiol, 1988 Aug;128(2):337-42.
  96. Nielson CM, Harris RB, et al. Risk factors for anogenital human papillomavirus infection in men. J Infect Dis, 2007 Oct 15;196(8):1137-45.
  97. Smith EM, Ritchie JM, et al. Human papillomavirus prevalence and types in newborns and parents: concordance and modes of transmission. [See comment]. Sexually Transmitted Diseases, 2004 Jan;31(1):57-62.
  98. The FUTURE II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis, 2007;196(10):1438-46.
  99. Winer RL, Koutsky LA. Delivering reassurance to parents: perinatal human papillomavirus transmission is rare. [see comment]. Sex Transm Dis, 2004 Jan;31(1):63-4.
  100. Medeiros LR, Ethur AB, et al. Vertical transmission of the human papillomavirus: a systematic quantitative review. Cad Saude Publica, 2005 Jul-Aug;21(4):1006-15.
  101. Chaturvedi AK, Engels EA, et al. Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States. Journal of Clinical Oncology, 2011;29(32):4294-301.
  102. 1Attner P, Du J, et al. The role of human papillomavirus in the increased incidence of base of tongue cancer. Int J Cancer, 2010 June 15;126(12):2879-84.
  103. Chaturvedi AK, Engels EA, et al. Incidence Trends for Human Papillomavirus-Related and -Unrelated Oral Squamous Cell Carcinomas in the United States. Journal of Clinical Oncology, 2008;26(4):612-9.
  104. Gillison ML, Broutian T, et al. Prevalence of Oral HPV Infection in the United States, 2009-2010. JAMA, 2012;307(7):693-703.
  105. Näsman A, Attner P, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: An epidemic of viral-induced carcinoma? International Journal of Cancer, 2009;125(2):362-6.
  106. Steinau M, Saraiya M, et al. Human Papillomavirus Prevalence in Oropharyngeal Cancer Before Vaccine Introduction, United States. Emerging Infectious Diseases, 2014;20(5):822-8.
  107. Ou P, Gear K, et al. Human Papillomavirus and Oropharyngeal Squamous Cell Carcinoma: A New Zealand cohort study. ANZ J Surg, 2016 Sept 20.
  108. D'Souza G, Cullen K, et al. Differences in oral sexual behaviors by gender, age, and race explain observed differences in prevalence of oral human papillomavirus infection. PLoS One, 2014;9:e86023.
  109. Kreimer AR, Clifford GM, et al. Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A systematic review. Cancer Epidemiology Biomarkers & Prevention, 2005;14(2):467-75.
  110. Heck J, Berthiller J, et al. Sexual Behaviours and the Risk of Head and Neck Cancers: A pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int J Epidemiol, 2010;39(1):166-81.
  111. Fakhry C, Westra WH, et al. Improved Survival of Patients with Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical Trial. Journal of the National Cancer Institute, 2008;100(4):261-9.
  112. Ang KK, Harris J, et al. Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer. N Engl J Med, 2010;363:24-35.
  113. Gillison ML, Zhang Q, et al. Tobacco Smoking and Increased Risk of Death and Progression for Patients with p16-Positive and p16-Negative Oropharyngeal Cancer. J Clin Oncol, 2012;30(17):2102-11.
  114. Kimple R, Harari P. Is radiation dose reduction the right answer for HPV-positive head and neck cancer? Oral Oncol, 2014 Jun;50(6):560-4.
  115. Fakhry C, D'Souza G. Discussing the Diagnosis of HPV-OSCC: Common questions and answers. Oral Oncol, 2013;49(9):863-71.
  116. Kreimer AR. Prospects for prevention of HPV-driven oropharynx cancer. Oral Oncology, 2014;50(6):555-9.
  117. Ruiz R, Achlatis S, et al. Risk factors for adult-onset recurrent respiratory papillomatosis. Laryngoscope, 2014;124(10):2338-44.
  118. Lindeberg H, Elbrond O. Laryngeal Papillomas: the epidemiology in a Danish subpopulation 1965-1984. Clinical Otolaryngology, 1990;15(2):125-31.
  119. Shah K, Kashima H, et al. Rarity of caesarean section in cases of juvenile-onset respiratory papillomatosis. Obstet Gynecol, 1986;68(6):795-9.
  120. arson DA, Derkay CS. Epidemiology of recurrent respiratory papillomatosis. APMIS, 2010;118(6-7):450-4.
  121. Kashima H, Shah F, et al. A comparison of risk factors in juvenile-onset and adult-onset recurrent respiratory papillomatosis. Laryngoscope, 1992;102:9-13.
  122. Novakovic D, Cheng A, et al. Juvenile Recurrent Respiratory Papillomatosis: 10-year audit and Australian prevalence estimates. The Laryngoscope, 2016;126(12):2827-32.
  123. CDC. Condyloma acuminatum - United States, 1966-1981; MMWR; 1983 Jun 17; 32(22):306-8.
  124. Dinh TH, Sternberg M, et al. Genital warts among 18- to 59-year-olds in the United States, national health and nutrition examination survey, 1999-2004. [Erratum in: Sex Transm Dis 2008 Aug;35(8):772-3.]. Sex Transm Dis, 2008 Apr;25(4):357-60.
  125. Dunne EF, Unger ER, et al. Prevalence of HPV infection among females in the United States. JAMA, 2007;297(8):813-9.
  126. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med, 1997 May 5;102(5A):3-8.
  127. Cohen BA, Honig P, et al. Anogenital warts in children. Clinical and virologic evaluation for sexual abuse. [See comment]. Archives of Dermatology, 1990 Dec;126(12):1575-80.
  128. Oriel JD. Sexually transmitted diseases in children: human papillomavirus infection. Genitourin Med, 1992 Apr;68(2):80-3.
  129. Rice PS, Mant C, et al. High prevalence of human papillomavirus type 16 infection among children. J Med Virol, 2000 May;61(1):70-5.
  130. Dunne EF, Karem KL, et al. Seroprevalence of human papillomavirus type 16 in children. J Infect Dis, 2005 Jun 1;191(11):1817-9.
  131. Boyd AS. Condylomata acuminata in the pediatric population. [See comment]. Am J Dis Child, 1990 Jul;144(7):817-24.
  132. Moscicki AB. Genital HPV infections in children and adolescents. Obstet Gynecol Clin North Am, 1996 Sep;23(3):675-97.
  133. Gutman LT, St Claire K, et al. Evaluation of sexually abused and nonabused young girls for intravaginal human papillomavirus infection. Am J Dis Child, 1992 Jun;146(6):694-9.
  134. Allen AL, Siegfried EC. The natural history of condyloma in children. J Am Acad Dermatol, 1998 Dec;39(6):951-5.
  135. Cripe TP. Human papillomaviruses: pediatric perspectives on a family of multifaceted tumorigenic pathogens. [See comment]. Pediatr Infect Dis J, 1990 Nov;9(11):836-44.
  136. Formar AB, Prendiville JS. Association of human immunodeficiency virus seropositivity and extensive perineal condylomata acuminata in a child. Archives of Dermatology, 1988 Jul;124(7):1010-1.
  137. Siegfried EC, Frasier LD. Anogenital warts in children. Adv Dermatol, 1997;12:141-66; discussion 67.
  138. Padel AF, Venning VA, et al. Human papillomaviruses in anogenital warts in children: typing by in situ hybridisation. [See comment]. Bmj, 1990 Jun 9;300(6738):1491-4.
  139. Davis AJ, Emans SJ. Human papilloma virus infection in the pediatric and adolescent patient. [See comment]. J Pediatr, 1989 Jul;115(1):1-9.
  140. Spitzer M, Krumholz BA, et al. The multicentric nature of disease related to human papillomavirus infection of the female lower genital tract. Obstetrics & Gynecology, 1989 Mar;73(3 Pt 1):303-7.
  141. Stevens-Simon C, Nelligan D, et al. The prevalence of genital human papillomavirus infections in abused and nonabused preadolescent girls. Pediatrics, 2000 Oct;106(4):645-9.
  142. Handley J, Hanks E, et al. Common association of HPV 2 with anogenital warts in prepubertal children. Pediatr Dermatol, 1997 Sep-Oct;14(5):339-43.
  143. Raimer SS, Raimer BG. Family violence, child abuse, and anogenital warts. Archives of Dermatology, 1992 Jun;128(6):842-4.
  144. Mammas IN, Sourvinos G, et al. Novel human papilloma virus (HPV) genotypes in children with recurrent respiratory papillomatosis. European Journal of Pediatrics, 2010 Aug;169(8):1017-21.
  145. Bennett RS, Powell KR. Human papillomaviruses: associations between laryngeal papillomas and genital warts. Pediatr Infect Dis J, 1987 Mar;6(3):229-32.
  146. Boutselis JG. Intraepithelial carcinoma of the vulva. American Journal of Obstetrics & Gynecology, 1972 Jul 15;113(6):733-8.
  147. Lister UM, Akinla O. Carcinoma of the vulva in childhood. J Obstet Gynaecol Br Commonw, 1972 May;79(5):470-3.
  148. Godfrey JC, Vaughan MC, et al. Successful treatment of bowenoid papulosis in a 9-year-old girl with vertically acquired human immunodeficiency virus. Paediatrics, 2003;112(1 Pt 1):e73-6.
  149. Breneman DL, Lucky AW, et al. Bowenoid papulosis of the genitalia associated with human papillomavirus DNA type 16 in an infant with atopic dermatitis. Pediatr Dermatol, 1985;2(4):297-301.
  150. Unger ER, Fajman NN, et al. Anogenital Human Papillomavirus in Sexually Abused and Nonabused Children: A Multicenter Study. Pediatrics, 2011 Aug 15;128(3):e658-65.
  151. McCoy CR, Applebaum H, et al. Condyloma acuminata: an unusual presentation of child abuse. Journal of Pediatric Surgery, 1982 Oct;17(5):505-7.
  152. 152. Doerfler D, Bernhaus A, et al. Human papilloma virus infection prior to coitarche. American Journal of Obstetrics & Gynecology, 2009 May;200(5):487.e1-5.
  153. Mant C, Kell B, et al. Buccal exposure to human papillomavirus type 16 is a common yet transitory event of childhood. J Med Virol, 2003 Dec;71(4):593-8.
  154. Myhre AK, Dalen A, et al. Anogenital human papillomavirus in non-abused preschool children. Acta Paediatr, 2003 Dec;92(12):1445-52.
  155. Powell J, Strauss S, et al. Genital carriage of human papilloma virus (HPV) DNA in prepubertal girls with and without vulval disease. Pediatr Dermatol, 2003 May-Jun;20(3):191-4.
  156. Sinal SH, Woods CR. Human papillomavirus infections of the genital and respiratory tracts in young children. Seminars in Pediatric Infectious Diseases, 2005 Oct;16(4):306-16.
  157. Sinclair KA, Woods CR, et al. Anogenital and respiratory tract human papillomavirus infections among children: age, gender, and potential transmission through sexual abuse. Pediatrics, 2005 Oct;116(4):815-25.
  158. Syrjnen S. Current concepts on human papillomavirus infections in children. APMIS, 2010 Jun;118(6-7):494-509.
  159. Syrjnen S, Puranen M. Human papillomavirus infections in children: the potential role of maternal transmission. Critical Reviews in Oral Biology & Medicine, 2000;11(2):259-74.
  160. Jenny C, Crawford-Jakubiak J. Committee on Child Abuse and Neglect; American Academy of Pediatrics. The evaluation of children in the primary care setting when sexual abuse is suspected. Pediatrics, 2013 Aug;132(2):e558-67.
  161. Watts DH, Koutsky LA, et al. Low risk of perinatal transmission of human papillomavirus: results from a prospective cohort study. [See comment]. American Journal of Obstetrics & Gynecology, 1998 Feb;178(2):365-73.
  162. Rintala MA, Grenman SE, et al. Transmission of high-risk human papillomavirus (HPV) between parents and infant: a prospective study of HPV in families in Finland. Journal of Clinical Microbiology, 2005 Jan;43(1):376-81.
  163. Castellsagué X, Drudis T, et al. Human Papillomavirus (HPV) infection in pregnant women and mother-to-child transmission of genital HPV genotypes: a prospective study in Spain. BMC Infectious Diseases, 2009 May 27;9:74.
  164. Campisi P, Hawkes M, et al. The epidemiology of juvenile onset recurrent respiratory papillomatosis derived from a population level national database. Laryngoscope, 2010 Jun;120(6):1233-45.
  165. Hanson RM, Glasson M, et al. Anogenital warts in childhood. [See comment]. Child Abuse & Neglect, 1989;13(2):225-33.
  166. Herman-Giddens ME, Gutman LT, et al. Association of coexisting vaginal infections and multiple abusers in female children with genital warts. Sexually Transmitted Diseases, 1988 Jan-Mar;15(1):63-7.
  167. Sinclair KA, Woods CR, et al. Venereal warts in children. Pediatrics in Review, 2011 Mar;32(3):115-21.
  168. Goldenring JM. Secondary syphilis in a prepubertal child. Differentiating condyloma lata from condyloma acuminata. NY State Journal of Medicine, 1989 Mar;89(3):180-1.
  169. Kelly P, Koh J. Sexually transmitted infections in alleged sexual abuse of children and adolescents. Journal of Paediatrics & Child Health, 2006 Jul-Aug;42(7-8):434-40.
  170. Boull C, Groth D. Update: Treatment of cutaneous viral warts in children. Pediatr Dermatol, 2011 May-Jun;28(3):217-29.
  171. Culton DA, Morrell DS, et al. The management of Condyloma Acuminata in the Pediatric Population. Pediatric Annals, 2009 Jul;38(7):368-72.
  172. Majewski S, Pniewski T, et al. Imiquimod is highly effective for extensive, hyperproliferative condyloma in children. Pediatr Dermatol, 2003 Sep-Oct;20(5):440-2.
  173. Goon P, Sonnex C, et al. Recurrent respiratory papillomatosis: an overview of current thinking and treatment. European Archives of Otorhinolaryngology, 2008 Feb;265(2):147-51.
  174. Zimmerman R, Nowalk M, et al. Randomized trial of an alternate human papillomavirus vaccine administration schedule in college-aged women. J Womens Health, 2010;19:1441-7.
  175. Neuzil K, Canh do G, et al. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial. JAMA, 2011;305:1424-31.
  176. Dobson S, McNeil S, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: A randomized clinical trial: Immunogenicity of HPV vaccine in girls vs women. JAMA 2013;309:1793-802.
  177. World Health Organization. Human papillomavirus vaccines: WHO position paper. Weekly Epidemiological Record, 2014 Oct;43:465-92.
  178. Garland SM, Kjaer SK, et al. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A systematic review of 10 years of real-world experience. Clinical Infectious Diseases, 2016;ciw354.
  179. Garland SM, Hernandez-Avila M, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med, 2007;356:1928-4.
  180. Group FIIS, Dillner J, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. Bmj, 2010;341:c3493.
  181. Group TFIS. Quadrivalent Vaccine Against Human Papillomavirus to Prevent High-Grade Cervical Lesions. N Engl J Med, 2007;356:1915-27.
  182. Joura EA, Garland SM, et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. Bmj, 2012;344:e1401.
  183. Joura EA, Giuliano AR, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med, 2015;372:711-23.
  184. Giuliano AR, Palefsky JM, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med, 2011;364:401-11.
  185. Rowhani-Rahbar A, Mao C, et al. Long-term efficacy of a prophylactic human papillomavirus type 16 vaccine abstract 25th International Papillomavirus Conference 8-14 May in Malmo, Sweden. 2009.
  186. Ault KA. Long-term efficacy of human papillomavirus vaccination. Gynecologic Oncology, 2007 Nov;107(2 Suppl 1):S27-30.
  187. Fraser C, Tomassini JE, et al. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine, 2007 May 22;25(21):4324-33.
  188. Delere Y, Wichmann O, et al. The Efficacy and Duration of Vaccine Protection Against Human Papillomavirus: A systematic review and meta-analysis. Dtsch Arztebl Int, 2014;111(35-36):584-91.
  189. Ferris D, Samakoses R, et al. Long term study of a quadrivalent human papilloma virus vaccine. 2014.
  190. Romanowski B. Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines. Hum Vaccin, 2011;7(2):161-9.
  191. Ali H, Donovan B, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. [Erratum appears in BMJ. 2013;346:F2942]. Bmj, 2013;346:f2032.
  192. Ali H, Guy RJ, et al. Decline in in-patient treatments of genital warts among young Australians following the national HPV vaccination program. BMC Infect Dis, 2013;13:140.
  193. Chow EPF, Read TRH, et al. Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme. Sex Transm Infect, 2015;91:214-9.
  194. Harrison C, Britt H, et al. Decreased management of genital warts in young women in Australian general practice post introduction of national HPV vaccination program: results from a nationally representative cross-sectional general practice study. PLoS ONE, 2014;9:e105967.
  195. Smith MA, Liu B, et al. Fall in genital warts diagnoses in the general and indigenous Australian population following implementation of a national human papillomavirus vaccination program: analysis of routinely collected national hospital data. J Infect Dis, 2015;211:91-9.
  196. Smith MA, Liu B, et al. Trends in genital warts by socioeconomic status after the introduction of the national HPV vaccination program in Australia: analysis of national hospital data. BMC Infect Dis, 2016;16:1.
  197. Mariani L, Vici P, et al. Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review. Adv Ther, 2015;32:10-30.
  198. Baldur-Felskov B, Dehlendorff C, et al. Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program. Cancer Causes Control, 2014;25:915-22.
  199. Leval A, Herweijer E, et al. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. J Natl Cancer Inst, 2013;105:469-74.
  200. Oliphant J, Stewart J, et al. Trends in genital warts diagnoses in New Zealand five years following the quadrivalent human papillomavirus vaccine introduction. NZMJ, 2017;130(1452).
  201. ESR Annual Surveillance Report 2015.
  202. Kumar D, Unger E, et al. Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients. American Journal of Transplantation, 2013;13:2411-7.
  203. Gomez-Lobo V, Whyte T, et al. Immunogenicity of a prophylactic quadrivalent human papillomavirus L1 virus-like particle vaccine in male and female adolescent transplant recipients. Pediatric Transplantation, 2014;18:310-5.
  204. Wilkin T, Lee J, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis, 2010;202(8):1246-53.
  205. Kojic E, Kang M, et al. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clinical Infectious Diseases, 2014;59(1):127-35.
  206. Jacobson D, Bousvaros A, et al. Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease. Inflammatory Bowel Diseases, 2013;19:1441.
  207. Vichnin M, Bonanni P, et al. An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015. Pediatr Infect Dis J, 2015;34:983-91.
  208. Gee J, Weinbaum C, et al. Quadrivalent HPV vaccine safety review and US safety monitoring plans for nine-valent HPV vaccine. Hum Vaccin Immunother;2016:1-12.
  209. Einstein M, Schiller J, et al. Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis, 2009;9:347-56.
  210. Mollers M, Vossen J, et al. Review: Current knowledge on the role of HPV antibodies after natural infection and vaccination: implications for monitoring an HPV vaccination programme. J Med Virol, 2013;85:1379-85.
  211. Mooij S, Landen O, et al. HPV seroconversion following anal and penile HPV infection in HIV-negative and HIV-infected MSM. Cancer Epidemiology Biomarkers & Prevention, 2014;23:2455-61.
  212. Stanley M, Pinto L, et al. Human papillomavirus vaccines – immune responses. Vaccine 2012; 30:F83-F7, 2012;30:F83-7.
  213. Vriend H, Bogaards J, et al. Patterns of human papillomavirus DNA and antibody positivity in young males and females, suggesting a site-specific natural course of infection. PloS One, 2013;8:e60696.
  214. FDA Cervarix. Full prescribing information, 2009. (Accessed at http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm186981.pdf.)
  215. Malagon T, Drolet M, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and metaanalysis. Lancet Infect Dis, 2012;12:781-9.
  216. Koutsky LA, Harper DM. Chapter 13: Current findings from prophylactic HPV vaccine trials. Vaccine, 2006;24(Suppl 3):S114-21.


Share by: